Acadia Pharmaceuticals vs Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV is the larger business, with $1.26bn of revenue in fiscal 2025 against $1.07bn for Acadia Pharmaceuticals (1.2 times as much). Lakefront Biotherapeutics NV grew faster (321.6% against 11.9%). Acadia Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 36.5% against 28.9%. Acadia Pharmaceuticals carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Acadia PharmaceuticalsACAD, 2025 | Lakefront Biotherapeutics NVLKFT, 2025 |
|---|---|---|
| Revenue | $1.07bn | $1.26bn |
| Revenue growth | 11.9% | 321.6% |
| Net income | $391m | $363m |
| Operating margin | 9.8% | 26.5% |
| Net margin | 36.5% | 28.9% |
| Return on equity | 39.9% | 10.7% |
| Free cash flow | $105m | −$307m |
| Cash | $178m | $103m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 798 | — |
| Market value | $3.55bn | $2.11bn |
| Price vs our value range | — | — |
| Moat score | 44 (Weak) | — |
| Insider trades, 12 months | 0 buys, 25 sales | 0 buys, 0 sales |